Premium
CI‐911: A placebo‐controlled study in patients with primary degenerative dementia
Author(s) -
Dysken Maurice W.,
AntonJohnson Susan,
Klein Linda,
Kuskowski Michael,
Schut Lawrence J.,
Miles Steven H.,
Maletta Gabe J.,
De Jong Richard
Publication year - 1988
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430120309
Subject(s) - dementia , placebo , cognition , primary care , psychology , medicine , clinical psychology , physical therapy , psychiatry , physical medicine and rehabilitation , gerontology , alternative medicine , disease , pathology , family medicine
Twenty patients with primary degenerative dementia participated in a 6‐week, doseranging, double‐blind, placebo‐controlled study of Cl‐911, a cognition activator that enhances performance in animal models of impaired cognition. Cl‐911 was well tolerated in these patients, but it did not result in significant improvement on objective measures of cognition, social functioning, or self‐care.